Epidemic Intelligence Service, Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Clin Infect Dis. 2021 Mar 15;72(6):961-967. doi: 10.1093/cid/ciaa180.
Neurosyphilis, a complication of syphilis, can occur at any stage of infection. Measuring the prevalence of neurosyphilis is challenging, and there are limited data on the prevalence of neurologic or ocular symptoms among patients with syphilis. We sought to describe the prevalence of neurologic and/or ocular symptoms among early syphilis (ES) cases and the clinical management of symptomatic cases enrolled in the STD Surveillance Network (SSuN) Neuro/Ocular Syphilis Surveillance project.
Persons diagnosed with ES were selected for interviews based on current health department protocols in 5 participating SSuN jurisdictions from November 2016 through October 2017. All interviewed ES cases were screened for self-reported neurologic and/or ocular symptoms. Additional clinical information on diagnostic testing and treatment for cases concerning for neurosyphilis/ocular syphilis was obtained from providers.
Among 9123 patients with ES who were interviewed, 151 (1.7%; 95% confidence interval [CI], 1.4%-1.9%) reported ≥ 1 neurologic or ocular symptom. Of the 53 (35%) who underwent lumbar puncture, 22 (42%) had documented abnormal cerebrospinal fluid, of which 21 (95%) were treated for neurosyphilis/ocular syphilis. Among the remaining 98 symptomatic patients with no documented lumbar puncture (65%), 12 (12%) were treated for and/or clinically diagnosed with neurosyphilis/ocular syphilis.
We observed a low prevalence of self-reported neurologic and/or ocular symptoms in interviewed ES cases. Approximately one-third of ES cases who self-reported symptoms underwent further recommended diagnostic evaluation. Understanding barriers to appropriate clinical evaluation is important to ensuring appropriate management of patients with possible neurologic and/or ocular manifestations of syphilis.
神经梅毒是梅毒的一种并发症,可发生在感染的任何阶段。测量神经梅毒的患病率具有挑战性,并且有关梅毒患者神经或眼部症状患病率的数据有限。我们旨在描述早期梅毒(ES)病例中神经和/或眼部症状的患病率,以及在性传播疾病监测网络(SSuN)神经/眼部梅毒监测项目中纳入的有症状病例的临床管理。
根据 5 个参与 SSuN 司法管辖区的现行卫生部门方案,从 2016 年 11 月至 2017 年 10 月,选择诊断为 ES 的患者进行访谈。所有接受访谈的 ES 病例均筛查有无自述神经和/或眼部症状。从提供者处获得有关疑似神经梅毒/眼部梅毒病例的诊断检测和治疗的其他临床信息。
在接受访谈的 9123 例 ES 患者中,有 151 例(1.7%;95%置信区间 [CI],1.4%-1.9%)报告有≥1 种神经或眼部症状。在 53 例(35%)进行腰椎穿刺的患者中,有 22 例(42%)脑脊液异常,其中 21 例(95%)接受了神经梅毒/眼部梅毒治疗。在其余 98 例无记录腰椎穿刺但自述有症状的患者中(65%),有 12 例(12%)接受了神经梅毒/眼部梅毒治疗和/或临床诊断。
我们观察到接受访谈的 ES 病例中自述神经和/或眼部症状的患病率较低。大约三分之一自述有症状的 ES 病例接受了进一步推荐的诊断评估。了解适当临床评估的障碍对于确保对可能有神经和/或眼部梅毒表现的患者进行适当管理很重要。